Angiology

OncXerna Therapeutics to Present at The LifeSci Partners Private Company Summer Symposium

Retrieved on: 
Monday, July 19, 2021
Branches of biology, Biology, Angiology, Medical specialties, Growth factors, Bayer, Kenilworth, New Jersey, Merck & Co., Schering-Plough, Vascular endothelial growth factor, Angiogenesis inhibitor, Angiogenesis

WALTHAM, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (OncXerna), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the LifeSci Partners Private Company Summer Symposium taking place virtually from July 21-23, 2021.

Key Points: 
  • WALTHAM, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (OncXerna), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the LifeSci Partners Private Company Summer Symposium taking place virtually from July 21-23, 2021.
  • OncXernas approach pairs those patients with OncXernas clinical-stage therapies and known mechanism of action that directly address these biologies, with the goal to substantially improve patient outcomes.
  • OncXerna is targeting patients whose dominant tumor biology is driven by angiogenesis with a focus beyond VEGF to include broader anti-angiogenic pathways.
  • KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Notal Vision announces publication of first prospective longitudinal pilot study of daily self-imaging with patient-operated Home OCT in wet AMD patients

Retrieved on: 
Tuesday, July 13, 2021
Branches of biology, Ophthalmology, Clinical medicine, Angiology, Anti–vascular endothelial growth factor therapy, Macular degeneration, Vascular endothelial growth factor

The study evaluated the ability of subjects to perform sequential daily self-imaging of their eyes with the user-friendly, tele-connected and self-operated Notal Home OCT device in their homes.

Key Points: 
  • The study evaluated the ability of subjects to perform sequential daily self-imaging of their eyes with the user-friendly, tele-connected and self-operated Notal Home OCT device in their homes.
  • Led by Prof. Loewenstein, the pilot study in Israel followed four patients undergoing routine anti-VEGF therapy for wet AMD in one or both eyes for up to three months.
  • Prospective longitudinal pilot study: daily self-imaging with patient-operated home OCT in neovascular age-related macular degeneration.
  • Notal Visions Home OCT system will enable wet AMD patients to perform technician-free OCTtesting at home with rapid and self-guided fixation critical components, especially for elderly patients frequently with pre-existing vision loss.

Endovascular Aneurysm Repair (EVAR) Market Report 2021: Global Industry Trends, Share, Size, Growth, Opportunity and Forecasts, 2015-2020 & 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 5, 2021
Hospitals, Pharmaceutical, Health, Medical specialties, Angiology, Cardiovascular system, Vascular surgery, Vascular diseases, Interventional radiology, Endovascular aneurysm repair, Evar, Aneurysm, Neurosurgery, Open aortic surgery, Aortic aneurysm

The "Endovascular Aneurysm Repair (EVAR) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Endovascular Aneurysm Repair (EVAR) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global endovascular aneurysm repair market exhibited moderate growth during 2015-2020.
  • Looking forward, the global endovascular aneurysm repair market to grow at a CAGR of around 5% during the forecast period (2021-2026).
  • Due to the prevalence of aneurysms, along with the growing geriatric population, endovascular treatment is increasingly being adopted by healthcare providers.

What is the Silent Killer? It's High Blood Pressure - Interview With Dr. Rajiv Agarwal

Retrieved on: 
Wednesday, June 30, 2021
Circulatory system, Cardiovascular system, Anatomy, Aging-associated diseases, Heart diseases, Cardiovascular physiology, Angiology, Hypertension, Cardiology, Coronary artery disease, Peripheral artery disease, Heart failure

HOUSTON, June 30, 2021 /PRNewswire/ -- In this interview, Dr. Rajiv Agarwal , board-certified cardiologist at Modern Heart and Vascular Institute , talked about how understanding blood pressure can help prevent heart attacks and strokes.

Key Points: 
  • HOUSTON, June 30, 2021 /PRNewswire/ -- In this interview, Dr. Rajiv Agarwal , board-certified cardiologist at Modern Heart and Vascular Institute , talked about how understanding blood pressure can help prevent heart attacks and strokes.
  • Dr. Agarwal talked about the importance of diagnosing symptoms of high blood pressure, causes and treatments to help patients.With a focus on prevention, there are many steps people can take to control hypertension.
  • To learn more about high blood pressure, please click here .
  • Modern Heart and Vascular Institute assists with variousheart & vascular symptoms & issues such as chest pain, high cholesterol, congestive heart failure, peripheral arterial disease (PAD), arrhythmia, coronary artery disease, high blood pressure and much more.

REPEAT - New Psychedelic Drug Formula Believed to Work to Mitigate Neurological Damage Due to Stroke, Provisional Patent Application Filed

Retrieved on: 
Monday, June 21, 2021
Intellectual property law, Medical specialties, Angiology, Amines, Ischemia, Stroke, United States Patent and Trademark Office, Patent application, N,N-Dimethyltryptamine, Blood

A provisional matter of composition patent application for AKO001 has been filed with the United States Patent and Trademark Office (USPTO) under application 63147343.

Key Points: 
  • A provisional matter of composition patent application for AKO001 has been filed with the United States Patent and Trademark Office (USPTO) under application 63147343.
  • Ischemia is a condition in which the blood vessels become blocked, and blood flow is stopped or reduced.
  • When blood flow is diminished to a body part, that body part also does not receive adequate oxygen.
  • Akomes specifically chosen plant bioactive and DMT are an ideal combination of compounds for mitigating the neurological damage caused by ischemic strokes.

New Psychedelic Drug Formula Believed to Work to Mitigate Neurological Damage Due to Stroke, Provisional Patent Application Filed

Retrieved on: 
Saturday, June 19, 2021
Intellectual property law, Medical specialties, Angiology, Amines, Ischemia, Stroke, United States Patent and Trademark Office, Patent application, N,N-Dimethyltryptamine, Blood

A provisional matter of composition patent application for AKO001 has been filed with the United States Patent and Trademark Office (USPTO) under application 63147343.

Key Points: 
  • A provisional matter of composition patent application for AKO001 has been filed with the United States Patent and Trademark Office (USPTO) under application 63147343.
  • Ischemia is a condition in which the blood vessels become blocked, and blood flow is stopped or reduced.
  • When blood flow is diminished to a body part, that body part also does not receive adequate oxygen.
  • Akomes specifically chosen plant bioactive and DMT are an ideal combination of compounds for mitigating the neurological damage caused by ischemic strokes.

Society for Vascular Medicine Elects Dr. Herb Aronow as its New President

Retrieved on: 
Friday, June 18, 2021
Vascular Medicine, Angiology

CHICAGO, June 18, 2021 /PRNewswire/ --Herbert D. Aronow, MD, MPH, FSVM is the new president of the Society for Vascular Medicine.

Key Points: 
  • CHICAGO, June 18, 2021 /PRNewswire/ --Herbert D. Aronow, MD, MPH, FSVM is the new president of the Society for Vascular Medicine.
  • Aronow has been active as a leader in the Society during his 16 years of membership, having served two terms each as a Trustee-At-Large, Secretary, and President-Elect.
  • "It is an honor to serve as SVM's next President and I look forward to working alongside the Board of Trustees and other Society leaders to advance the vascular medicine discipline and the care of vascular patients," Aronow said.
  • The Society for Vascular Medicine (SVM) is a professional organization founded in 1989 to improve the integration of vascular biological advances into medical practice, and to maintain high standards of clinical vascular medicine.

BioHarvest Sciences Inc. Reveals VINIA Anti-Aging Capabilities via Blood Flow Improvement

Retrieved on: 
Tuesday, June 15, 2021
Branches of biology, Anatomy, Angiology, Cardiovascular physiology, Medical specialties, Blood vessel, Artery, Blood, Constriction, Hemodynamics

VINIA(R)'s ability to increase dilation of arteries and to reduce blood vessel constriction allows it to fight the human aging process

Key Points: 
  • As we age, our bodies produce more ET1 (a vaso-constrictor) and less NO (a vaso-dilator), causing arteries and blood vessels to constrict and stiffen.
  • Improvement of blood and oxygen supply benefits all of the body's organs and tissues and contributes to overall health and wellness.
  • "We launched VINIA in the US in May 2021, but we have been monitoring all supplement products in the area of blood flow for many years."
  • The first video is now available , and it demonstrates the unique "double-action" effect" by which VINIA increases the dilation of arteries and reduces blood vessel constriction in the body.

Medical Vein Clinic Announces Expansion of Services to Treat Patients with Lymphatic Disease

Retrieved on: 
Tuesday, June 15, 2021
Medical specialties, Angiology, Circulatory system, Vascular surgery, Varicose veins, Vein, Edema, Vascular diseases, Vein disorders

Dr. Trock will complement the clinic's varicose vein treatment experts, extending their services to care for patients suffering from lymphatic disease.

Key Points: 
  • Dr. Trock will complement the clinic's varicose vein treatment experts, extending their services to care for patients suffering from lymphatic disease.
  • He is dedicated to evaluating and educating patients along with developing home treatment plans to resolve vein pain and swelling associated with vein disease.
  • "Early detection and treatment of vein and lymphatic disease is critical to prevent patients from experiencing a decline in physical functions and becoming debilitated," noted Dr. John Hogg, founder of Medical Vein Clinic.
  • Medical Vein Clinic has treated thousands of patients with vein and lymphatic disease, helping them lead fuller, healthier lives.

OXURION Completes Patient Enrollment for Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)

Retrieved on: 
Tuesday, June 8, 2021
Branches of biology, Clinical medicine, Medicine, Angiology, Anti–vascular endothelial growth factor therapy, Vascular endothelial growth factor, Diabetic retinopathy, Macular edema, Kallikrein, Conbercept

Dose selection data from Part A of the study is expected in the second half of 2021.

Key Points: 
  • Dose selection data from Part A of the study is expected in the second half of 2021.
  • THR-149 acts through inhibition of the plasma kallikrein-kinin (PKaI-Kinin) system, a validated VEGF-independent target for DME.
  • The Phase 2 KALAHARI study is a two part, randomized, prospective, multi-center study assessing multiple (3) injections of THR-149 in DME patients who suboptimally respond to anti-VEGF therapy.
  • This patient population currently does not have adequate treatment options and represents a critical area of unmet medical need in the treatment of diabetic macular edema.